Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week Phase IIb trial of atacicept in systemic lupus erythematosus
2013-002773-21Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Atacicept with Placebo (2 arms). Primary endpoint: SRI response at Week 24. Started Dec 2013; status: completed.
02
Drugs
atacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2013-002773-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002773-21.